시장보고서
상품코드
1429352

세계 뇌종양 치료제 시장 보고서(2024년)

Brain Tumor Drugs Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 175 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

뇌종양 치료제 시장 규모는 향후 수년간 대폭적인 성장이 예상되고 있습니다. 2028년 복합 연간 성장률(CAGR) 7.1%를 나타날 전망이며 50억 1,000만 달러로 성장할 것으로 예상됩니다. 예측되는 성장은 암 이환율 상승, 건강 관리비 증가, 노인 인구 증가, 강력한 의약품 파이프라인, 생물제제에 대한 FDA 규제의 개정에 의한 것으로 예상됩니다. 주요 동향으로는 뇌종양 치료를 위한 약물 조합에 대한 투자, 효능 향상을 위한 위상 제로 임상시험의 채용, 효능을 높이기 위한 약물전달 기술의 이용, 세포 및 유전자 치료 확대에의 주력, 전략적 합병,인수의 대처 등을 들 수 있습니다.

뇌종양 치료제 시장의 확대를 촉진하는 주요 계기는 세계에서 신경 질환의 만연입니다. 이러한 장애는 평균 수명 연장, 감염에 대한 노출 증가, 앉지 않은 라이프 스타일 등의 요인으로 인해 점점 더 확산되고 있습니다. 예를 들어 미국 뇌종양협회의 보고에 따르면 현재 미국에서는 약 70만 명이 원발성 뇌종양을 앓고 있으며, 86,000명이 진단을 받을 것으로 예상되고 있습니다. 뇌종양을 포함한 신경질환을 앓고 있는 사람 증가는 치료에 이용되는 약물 수요 증가에 직접 기여하여 뇌종양 치료제 시장의 성장을 가속하고 있습니다.

화학요법을 받는 환자 수의 급증으로 뇌종양 치료제의 지속적인 확대가 예상되고 있습니다. 화학요법은 암세포 등 급속하게 분열하는 세포를 표적으로 하여 근절하는 강력한 약제를 사용하는 중요한 의료 접근법이며, 여전히 뇌종양의 기초치료입니다. 효과적인 화학요법제의 개발과 가용성은 전체 치료 계획의 성공에 크게 영향을 미칩니다. 화학요법의 효능은 환자의 생존율에 큰 영향을 주고, 삶의 질을 향상시키고, 시장 상황에 큰 영향을 미칩니다. 예를 들어 2023년 7월의 질병 관리 예방 센터의 데이터에 따르면, 미국에서는 매년 100만명이 넘는 암 환자가 화학요법 또는 방사선요법을 받고 있습니다. 그 결과, 화학요법을 선택하는 환자 수 증가는 뇌종양 치료제 시장의 성장 궤도를 추진하는 매우 중요한 추진력으로 작용합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나,러시아 전쟁이 시장에 미치는 영향
  • COVID-19에 의한 시장에 대한 영향

제5장 세계 시장 규모와 성장

  • 세계 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계 시장 규모 실적과 성장(2018년-2023년)
  • 세계 시장 규모 예측과 성장(2023년-2028년, 2033년)

제6장 시장 세분화

  • 세계 뇌종양 치료제 시장 : 유형별 세분화, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 수모종
  • 성상세포종
  • 희돌기 교종
  • 원시신경외배엽(PNET)
  • 기타(신경교종, 청신경종, 수막종)
  • 세계 뇌종양 치료제 시장 : 약제별 세분화, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 테모졸로미드
  • 칼무스틴
  • 시스플라틴
  • 베바시주맙
  • 게프티닙
  • 엘로티닙
  • 세계 뇌종양 치료제 시장 : 최종 사용자별 세분화, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 병원 약국
  • 클리닉
  • 기타 최종 사용자

제7장 지역 및 국가 분석

  • 세계 뇌종양 치료제 시장 : 지역별, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 세계 뇌종양 치료제 시장 : 국가별, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

  • 뇌종양 치료제 시장 경쟁 구도
  • 뇌종양 치료제 시장 기업 프로파일
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Amgen Inc.
    • Pfizer Inc.
    • Merck &Co. Inc.

제31장 기타 선도적이고 혁신적인 기업

  • CordenPharma
  • Eisai Co., Ltd.
  • Emcure Pharmaceuticals Limited
  • AstraZeneca
  • Y-mAbs Therapeutics
  • Roche India
  • Novartis Oncology
  • Arlak Biotech
  • Healthkind Labs Pvt. Ltd.
  • SwisscheM Healthcare Pvt.Ltd
  • Apikos Pharma
  • Kolaz Biotech
  • CStone Pharma
  • CARsgen Therapeutics
  • JW Therapeutics

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 미래 전망과 가능성 분석

제36장 부록

BJH 24.03.21

Brain tumor drugs are medications utilized in the treatment of brain tumors, employing a range of approaches including chemotherapy, hormone therapies, anticonvulsants, and painkillers. While certain prescription drugs aim to manage symptoms during tumor treatment, chemotherapy specifically targets the reduction or destruction of brain tumors.

Key drugs in the realm of brain tumor treatment include temozolomide, carmustine, cisplatin, bevacizumab, gefitinib, and erlotinib. Temozolomide, for instance, is designed to treat specific types of brain cancer such as glioblastomamultiforme and anaplastic astrocytoma. These drugs fall under the category of antineoplastics, focusing on combating cancer. Various types of brain tumors, such as medulloblastoma, astrocytoma, oligodendroglioma, primitive neuroectodermal (PNET), and others such as glioma, acoustic neuroma, and meningioma, are addressed using these drugs. The sectors benefiting from these treatments include hospital pharmacies, clinics, and other healthcare facilities.

The brain tumor drugs market research report is one of a series of new reports from The Business Research Company that provides brain tumor drugs market statistics, including brain tumor drugs industry global market size, regional shares, competitors with a brain tumor drugs market share, detailed brain tumor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the brain tumor drugs industry. This brain tumor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The brain tumor drugs market size has grown strongly in recent years. It will grow from $3.55 billion in 2023 to $3.81 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The historical growth can be attributed to several factors, including a rising prevalence of neurological disorders, increased healthcare expenditure, a higher number of approvals for oncology (cancer) drugs, an upsurge in pharmaceutical research and development (R&D) expenditure, and advancements in cancer drug discovery.

The brain tumor drugs market size is expected to see strong growth in the next few years. It will grow to $5.01 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. Forecasted growth is attributed to rising cancer rates, increased healthcare spending, a growing elderly population, a robust drug pipeline, and revised FDA regulations for biologics. Major trends include investing in drug combinations for brain tumor treatment, adopting phase zero clinical trials for efficacy improvement, using technology in drug delivery for enhanced effectiveness, focusing on expanding cell and gene therapy, and engaging in strategic mergers and acquisitions.

The primary catalyst fueling the expansion of the Brain Tumor drugs market is the escalating prevalence of Neurological Disorders on a global scale. These disorders have become increasingly prevalent due to factors such as longer life expectancy, heightened exposure to infections, and sedentary lifestyles. For instance, as reported by the National Brain Tumor Society, approximately 700,000 individuals in the United States are currently affected by primary brain tumors, with an additional 86,000 expected to receive diagnoses. This growing population of individuals with neurological disorders, including brain tumors, is directly contributing to the increased demand for drugs utilized in their treatment, thereby fostering the growth of the brain tumor drugs market.

The surge in the number of patients undergoing chemotherapy is poised to drive the continued expansion of brain tumor drugs. Chemotherapy, a vital medical approach employing potent drugs to target and eradicate rapidly dividing cells such as cancer cells, remains a cornerstone treatment for brain tumors. The development and accessibility of effective chemotherapy drugs significantly influence the overall success of treatment regimens. The efficacy of chemotherapy profoundly impacts patient survival rates and enhances their quality of life, exerting a substantial influence on the market landscape. For instance, based on data from the Centers for Disease Control and Prevention in July 2023, over 1 million cancer patients in the United States undergo chemotherapy or radiation therapy annually. Consequently, the escalating number of patients opting for chemotherapy serves as a pivotal driver propelling the growth trajectory of the brain tumor drugs market.

Companies within the brain tumor drugs market are increasingly turning towards nanotechnology for treatment methodologies. Nanoparticles are being utilized as carriers for drugs, delivering them directly to cancer cells or into the tumor, yielding advantages such as reduced drug dosage, enhanced shelf life, and minimized toxicity. Some nanodrugs have proven effective in surmounting the blood-brain barrier, a historically significant challenge in treating brain tumors. Notably, nanoparticles such as Liposomes have facilitated targeted drug delivery to the core of cancer cells. Moreover, when coated with transferrin, these particles can breach the blood-brain barrier. Esteemed industry players such as GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Merck & Company Inc., Pfizer, Inc., and Celgene Corporation are actively embracing this technology to advance medication and treatment techniques.

Key industry entities within the brain tumor drugs market are heavily invested in the development and approval of novel drugs, aiming to gain a competitive advantage. Drug approvals represent the regulatory process by which government health agencies authorize the marketing, sale, and prescription of new medications for specific medical conditions. For example, in June 2022, the United States Food and Drug Administration granted accelerated approval for a novel treatment combination incorporating the oral drugs dabrafenib (Tafinlar) and trametinib (Mekinist) for advanced brain tumors exhibiting the BRAF V600E mutation. This approval extends to both adult and pediatric patients with high- and low-grade gliomas that have progressed post-prior treatments. Encouraging results from clinical trials revealed significant tumor reduction among patients receiving the combination therapy. Notably, positive responses were observed in 33% of high-grade glioma patients, 50% of low-grade glioma patients, and 25% of pediatric glioma patients. The BRAF V600E mutation is prevalent across various glioma types, including low-grade gliomas, pleomorphic xanthoastrocytomas (PXA), gangliogliomas, and pilocytic astrocytomas.

In December 2021, Sanofi, a French pharmaceutical company, completed the acquisition of Amunix Pharmaceuticals Inc. for a total of $1 billion. This strategic move positions Sanofi to advance its efforts in developing potentially transformative cancer therapies, particularly in the field of immuno-oncology. Amunix Pharmaceuticals Inc., a U.S.-based pharmaceutical company, brings valuable assets, including brain tumor drugs, to bolster Sanofi's capabilities in the oncology space.

Major companies operating in the brain tumor drugs market report are F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., CordenPharma, Eisai Co., Ltd., Emcure Pharmaceuticals Limited, AstraZeneca, Y-mAbs Therapeutics, Roche India, Novartis Oncology, Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd., Apikos Pharma, Kolaz Biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals (Japan), Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca PLC, GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, Sandoz AG, Eurofarma Laboratorios S.A., TUTEUR Argentina, The Takeda Pharmaceutical Company Limited, Pierre Fabre Group, Celnova Pharma, Pfizer S.R.L., Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, GlaxoSmithKline PLC, Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Eurolab, Aspen, Adcock Ingram.

North America was the largest region in the brain tumor drugs market in 2023. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market share during the forecast period. The regions covered in the brain tumor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the brain tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The brain tumor drugs market consists of sales Afinitor (Everolimus), Afinitor Disperz (Everolimus), Belzutifan, and Bevacizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Brain Tumor Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on brain tumor drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for brain tumor drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The brain tumor drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drugs: Temozolomide; Bevacizumab; Other Drugs
  • 2) By End User: Hospital Pharmacies; Retail Pharmacies/Drug Stores; Other End-Users
  • Companies Mentioned: F. Hoffmann-La Roche Ltd; Novartis AG; Amgen Inc.; Pfizer Inc.; Merck & Co. Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Brain Tumor Drugs Market Characteristics

3. Brain Tumor Drugs Market Trends And Strategies

4. Brain Tumor Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Brain Tumor Drugs Market Size and Growth

  • 5.1. Global Brain Tumor Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Brain Tumor Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Brain Tumor Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Brain Tumor Drugs Market Segmentation

  • 6.1. Global Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Medulloblastoma
  • Astrocytoma
  • Oligodendroglioma
  • Primitive Neuroectodermal (PNET)
  • Others (Glioma, Acoustic Neuroma, Meningioma)
  • 6.2. Global Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Temozolomide
  • Carmustine
  • Cisplatin
  • Bevacizumab
  • Geftinib
  • Erlotinib
  • 6.3. Global Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Clinics
  • Other End-Users

7. Brain Tumor Drugs Market Regional And Country Analysis

  • 7.1. Global Brain Tumor Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Brain Tumor Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Brain Tumor Drugs Market

  • 8.1. Asia-Pacific Brain Tumor Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Brain Tumor Drugs Market

  • 9.1. China Brain Tumor Drugs Market Overview
  • 9.2. China Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Brain Tumor Drugs Market

  • 10.1. India Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Brain Tumor Drugs Market

  • 11.1. Japan Brain Tumor Drugs Market Overview
  • 11.2. Japan Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Brain Tumor Drugs Market

  • 12.1. Australia Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Brain Tumor Drugs Market

  • 13.1. Indonesia Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Brain Tumor Drugs Market

  • 14.1. South Korea Brain Tumor Drugs Market Overview
  • 14.2. South Korea Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Brain Tumor Drugs Market

  • 15.1. Western Europe Brain Tumor Drugs Market Overview
  • 15.2. Western Europe Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Brain Tumor Drugs Market

  • 16.1. UK Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Brain Tumor Drugs Market

  • 17.1. Germany Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Brain Tumor Drugs Market

  • 18.1. France Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Brain Tumor Drugs Market

  • 19.1. Italy Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Brain Tumor Drugs Market

  • 20.1. Spain Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Brain Tumor Drugs Market

  • 21.1. Eastern Europe Brain Tumor Drugs Market Overview
  • 21.2. Eastern Europe Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Brain Tumor Drugs Market

  • 22.1. Russia Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Brain Tumor Drugs Market

  • 23.1. North America Brain Tumor Drugs Market Overview
  • 23.2. North America Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Brain Tumor Drugs Market

  • 24.1. USA Brain Tumor Drugs Market Overview
  • 24.2. USA Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Brain Tumor Drugs Market

  • 25.1. Canada Brain Tumor Drugs Market Overview
  • 25.2. Canada Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Brain Tumor Drugs Market

  • 26.1. South America Brain Tumor Drugs Market Overview
  • 26.2. South America Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Brain Tumor Drugs Market

  • 27.1. Brazil Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Brain Tumor Drugs Market

  • 28.1. Middle East Brain Tumor Drugs Market Overview
  • 28.2. Middle East Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Brain Tumor Drugs Market

  • 29.1. Africa Brain Tumor Drugs Market Overview
  • 29.2. Africa Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Brain Tumor Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Brain Tumor Drugs Market Competitive Landscape
  • 30.2. Brain Tumor Drugs Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Novartis AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Amgen Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Pfizer Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Merck & Co. Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Brain Tumor Drugs Market Other Major And Innovative Companies

  • 31.1. CordenPharma
  • 31.2. Eisai Co., Ltd.
  • 31.3. Emcure Pharmaceuticals Limited
  • 31.4. AstraZeneca
  • 31.5. Y-mAbs Therapeutics
  • 31.6. Roche India
  • 31.7. Novartis Oncology
  • 31.8. Arlak Biotech
  • 31.9. Healthkind Labs Pvt. Ltd.
  • 31.10. SwisscheM Healthcare Pvt.Ltd
  • 31.11. Apikos Pharma
  • 31.12. Kolaz Biotech
  • 31.13. CStone Pharma
  • 31.14. CARsgen Therapeutics
  • 31.15. JW Therapeutics

32. Global Brain Tumor Drugs Market Competitive Benchmarking

33. Global Brain Tumor Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Brain Tumor Drugs Market

35. Brain Tumor Drugs Market Future Outlook and Potential Analysis

  • 35.1 Brain Tumor Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Brain Tumor Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Brain Tumor Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제